[HTML][HTML] Genome sequencing in microfabricated high-density picolitre reactors
…, JR Knight, JR Lanza, JH Leamon, SM Lefkowitz, M Lei… - Nature, 2005 - nature.com
The proliferation of large-scale DNA-sequencing projects in recent years has driven a
search for alternative methods to reduce time and cost. Here we describe a scalable, highly …
search for alternative methods to reduce time and cost. Here we describe a scalable, highly …
The POT1–TPP1 telomere complex is a telomerase processivity factor
Telomeres were originally defined as chromosome caps that prevent the natural ends of
linear chromosomes from undergoing deleterious degradation and fusion events. POT1 (…
linear chromosomes from undergoing deleterious degradation and fusion events. POT1 (…
Mutations in a newly identified GTPase gene cause autosomal dominant hereditary spastic paraplegia
…, T Tukel, M Apak, T Heiman-Patterson, L Ming… - Nature …, 2001 - nature.com
The hereditary spastic paraplegias (HSPs; Strümpell-Lorrain syndrome, MIM number 18260)
are a diverse class of disorders characterized by insidiously progressive lower-extremity …
are a diverse class of disorders characterized by insidiously progressive lower-extremity …
[PDF][PDF] Neuropathy target esterase gene mutations cause motor neuron disease
…, M Bui, E Mark, D Thomas, D Tokarz, L Ming… - The American Journal of …, 2008 - cell.com
The possibility that organophosphorus (OP) compounds contribute to motor neuron disease
(MND) is supported by association of paraoxonase 1 polymorphisms with amyotrophic …
(MND) is supported by association of paraoxonase 1 polymorphisms with amyotrophic …
Structure of human POT1 bound to telomeric single-stranded DNA provides a model for chromosome end-protection
M Lei, ER Podell, TR Cech - Nature structural & molecular biology, 2004 - nature.com
The POT1 (protection of telomeres 1) protein binds the single-stranded overhang at the ends
of chromosomes in diverse eukaryotes. It is essential for chromosome end-protection in the …
of chromosomes in diverse eukaryotes. It is essential for chromosome end-protection in the …
[HTML][HTML] Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer
…, P Kocon, J Zhang, L Zhu, M Lei… - … England Journal of …, 2021 - Mass Medical Soc
Background No adjuvant treatment has been established for patients who remain at high
risk for recurrence after neoadjuvant chemoradiotherapy and surgery for esophageal or …
risk for recurrence after neoadjuvant chemoradiotherapy and surgery for esophageal or …
[HTML][HTML] Nivolumab combination therapy in advanced esophageal squamous-cell carcinoma
…, T Makino, I Xynos, X Liu, M Lei… - … England Journal of …, 2022 - Mass Medical Soc
Background First-line chemotherapy for advanced esophageal squamous-cell carcinoma
results in poor outcomes. The monoclonal antibody nivolumab has shown an overall survival …
results in poor outcomes. The monoclonal antibody nivolumab has shown an overall survival …
A long noncoding RNA maintains active chromatin to coordinate homeotic gene expression
…, A Protacio, RA Flynn, RA Gupta, J Wysocka, M Lei… - Nature, 2011 - nature.com
The genome is extensively transcribed into long intergenic noncoding RNAs (lincRNAs),
many of which are implicated in gene silencing 1 , 2 . Potential roles of lincRNAs in gene …
many of which are implicated in gene silencing 1 , 2 . Potential roles of lincRNAs in gene …
A hierarchy of timescales in protein dynamics is linked to enzyme catalysis
KA Henzler-Wildman, M Lei, V Thai, SJ Kerns… - Nature, 2007 - nature.com
The synergy between structure and dynamics is essential to the function of biological
macromolecules. Thermally driven dynamics on different timescales have been experimentally …
macromolecules. Thermally driven dynamics on different timescales have been experimentally …
First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma …
…, K Feeney, JM Cleary, V Poulart, D Cullen, M Lei… - The Lancet, 2021 - thelancet.com
Background First-line chemotherapy for advanced or metastatic human epidermal growth
factor receptor 2 (HER2)-negative gastric or gastro-oesophageal junction adenocarcinoma …
factor receptor 2 (HER2)-negative gastric or gastro-oesophageal junction adenocarcinoma …